BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 10334517)

  • 1. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Whitney CW; Sause W; Bundy BN; Malfetano JH; Hannigan EV; Fowler WC; Clarke-Pearson DL; Liao SY
    J Clin Oncol; 1999 May; 17(5):1339-48. PubMed ID: 10334517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG
    J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    Grigsby PW; Heydon K; Mutch DG; Kim RY; Eifel P
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):982-7. PubMed ID: 11704321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.
    Stehman FB; Ali S; Keys HM; Muderspach LI; Chafe WE; Gallup DG; Walker JL; Gersell D
    Am J Obstet Gynecol; 2007 Nov; 197(5):503.e1-6. PubMed ID: 17980189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group.
    Stehman FB; Bundy BN; Kucera PR; Deppe G; Reddy S; O'Connor DM
    Gynecol Oncol; 1997 Aug; 66(2):262-7. PubMed ID: 9264574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].
    Lindner H
    Strahlenther Onkol; 1998 Nov; 174(11):601-2. PubMed ID: 9830445
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
    Zhang M; Xu HD; Pan SD; Lin S; Yue JH; Liu JR
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):966-71. PubMed ID: 22138462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
    Rose PG; Java JJ; Whitney CW; Stehman FB; Lanciano R; Thomas GM
    Gynecol Oncol; 2014 Nov; 135(2):208-12. PubMed ID: 25152438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
    Varia MA; Bundy BN; Deppe G; Mannel R; Averette HE; Rose PG; Connelly P
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1015-23. PubMed ID: 9869224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
    Lorvidhaya V; Chitapanarux I; Sangruchi S; Lertsanguansinchai P; Kongthanarat Y; Tangkaratt S; Visetsiri E
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1226-32. PubMed ID: 12654431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
    Rose PG; Bundy BN; Watkins EB; Thigpen JT; Deppe G; Maiman MA; Clarke-Pearson DL; Insalaco S
    N Engl J Med; 1999 Apr; 340(15):1144-53. PubMed ID: 10202165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
    Gaffney DK; Winter K; Dicker AP; Miller B; Eifel PJ; Ryu J; Avizonis V; Fromm M; Greven K
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):104-9. PubMed ID: 17084549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.
    Christie DR; Bull CA; Gebski V; Langlands AO
    Radiother Oncol; 1995 Dec; 37(3):181-9. PubMed ID: 8746586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.
    Duenas-Gonzalez A; Lopez-Graniel C; Gonzalez-Enciso A; Mohar A; Rivera L; Mota A; Guadarrama R; Chanona G; De La Garza J
    Ann Oncol; 2002 Aug; 13(8):1212-9. PubMed ID: 12181244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.
    Lanciano R; Calkins A; Bundy BN; Parham G; Lucci JA; Moore DH; Monk BJ; O'Connor DM
    J Clin Oncol; 2005 Nov; 23(33):8289-95. PubMed ID: 16230678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.
    Monk BJ; Tian C; Rose PG; Lanciano R
    Gynecol Oncol; 2007 May; 105(2):427-33. PubMed ID: 17275889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
    Torres MA; Jhingran A; Thames HD; Levenback CF; Bodurka DC; Ramondetta LM; Eifel PJ
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):118-25. PubMed ID: 17869451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.